Video Experimental Relacionado
Updated: Sep 10, 2025
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.6K
Pemphigus inducido por gliptina
Avinash Jadhav1, Sandra Arora, Ashwini Dattatray Mundhe
1Department of Dermatology, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India.
Annals of African medicine
|August 20, 2025
Resumen
Este estudio de caso analiza el pénfigo inducido por gliptina, una rara afección de la piel que se desarrolla después de comenzar la medicación con gliptina para la diabetes. La identificación inmediata y la interrupción del medicamento es clave para confirmar este diagnóstico de pénfigo inducido por medicamentos.
Área de la Ciencia:
- Dermatología
- Endocrinología
- Farmacología
Sus antecedentes:
- El pénfigo puede ser idiopático o inducido por medicamentos, presentando características clínicas e histopatológicas similares.
- Las gliptinas se prescriben comúnmente para la diabetes mellitus tipo 2.
- Diferenciar el pénfigo inducido por fármacos de los casos idiopáticos es clínicamente significativo.
Objetivo del estudio:
- Para reportar un caso de pénfigo inducido por gliptina.
- Para enfatizar la importancia de un historial completo de medicamentos en el diagnóstico de las dermatosis inducidas por medicamentos.
- Para resaltar los criterios de diagnóstico para el pénfigo inducido por drogas.
Principales métodos:
- Un informe de caso que detalle la experiencia de un paciente con el tratamiento con gliptina y las lesiones cutáneas posteriores.
- Revisión de la presentación clínica, la histopatología y la historia clínica del paciente.
- Evaluación de la respuesta de la lesión tras el cese de la medicación sospechosa.
Principales resultados:
- El paciente desarrolló un pénfigo poco después de iniciar el tratamiento con gliptina.
- Los hallazgos clínicos e histopatológicos fueron consistentes con el pemfigo.
- Las lesiones cutáneas desaparecieron después de interrumpir el tratamiento con gliptina, lo que confirma la etiología inducida por el fármaco.
Conclusiones:
- El tratamiento con gliptina puede inducir el pénfigo, una afección que puede imitar el pénfigo idiopático.
- Un historial detallado de medicamentos es crucial para diagnosticar el pénfigo inducido por medicamentos.
- La interrupción del agente causante de la gliptina conduce a una mejoría, confirmando el diagnóstico.
Videos de Conceptos Relacionados
01:23Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
01:06Oral Hypoglycemic Agents: Glinides
257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:15Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
01:58Cell Specific Gene Expression
13.9K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.9K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K